Clinical usefussslness of glycated albumin in the diagnosis of diabetes: Results from an Italian study

Publication date: Available online 24 February 2018
Source:Clinical Biochemistry
Author(s): Chiara Bellia, Martina Zaninotto, Chiara Cosma, Luisa Agnello, Giulia Bivona, Mariela Marinova, Bruna Lo Sasso, Mario Plebani, Marcello Ciaccio
ObjectivesGlycated Albumin (GA) has been proposed as a screening marker for diabetes in Asian countries in the last years. Nevertheless, few studies have been conducted in Caucasian population. The aim of this study is to evaluate the clinical usefulness of GA in diabetes diagnosis in Caucasian asymptomatic subjects considered at risk of diabetes based on medical history and Fasting Plasma Glucose (FPG).Design and methodsThree hundred and thirty-four Caucasian subjects having one or more risk factor for diabetes, and/or FPG ranging from 5.6 mmol/L to 6.9 mmol/L with no symptoms for diabetes were enrolled in this study. Plasma GA was measured by an enzymatic method (quantILab Glycated Albumin) on ILab Taurus instrument (Instrumentation Laboratory - A Werfen Company).ResultsGA median levels were 13.2% (IQR:12.2–14.4). Eighteen subjects (5.4%) were classified as diabetics based on their HbA1c. According to the ROC curve analysis, GA identified subjects with diabetes with a sensitivity of 72.2% (95% CI: 46.5–90.3) and a specificity of 71.8% (95% CI: 66.5–76.7) (AUC: 0.80; 95% CI: 0.75–0.84; P < 0.0001) at the cut-off of 14%. The cut-off of 13.5% was associated to a higher sensitivity 88.9% (95%CI: 65.3–98.6) and a specificity of 60.4% (95%CI, 54.8–65.9).ConclusionsThis study confirms the clinical usefulness of GA for the diagnosis of diabetes in Caucasian subjects at risk for diabetes. More studies are required to clarify the role of GA in relation to the other diagnostic criteria for diabetes.



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2F3T8y8
via IFTTT